Iterum Therapeutics plc Ordinary Share
ITRMIterum Therapeutics plc is a clinical-stage pharmaceutical company focused on developing and commercializing innovative antibiotics for serious and life-threatening infections. The company aims to address the growing problem of antibiotic resistance by creating new therapies to treat resistant bacterial infections. Its pipeline includes oral and intravenous formulations designed to combat multidrug-resistant pathogens.
Company News
Iterum Therapeutics reports expanding market access for ORLYNVAHâ„¢, securing nearly 25% insurance coverage in the U.S. and signing a Medicare Part D rebate agreement with a top Pharmacy Benefit Manager, with potential coverage starting in Q1 2026.
Iterum Therapeutics will release its third quarter 2025 financial results on November 14, 2025, with a conference call to discuss results and provide a business update. The company has received FDA approval for ORLYNVAH, an oral antibiotic for treating urinary tract infections.
Iterum Therapeutics reported a Q2 2025 loss of $0.13 per share, higher than expected, as the company prepares for the commercial launch of its oral antibiotic ORLYNVAHâ„¢ for urinary tract infections. The company has secured manufacturing agreements and extended its cash runway into 2026.
Iterum Therapeutics plans to launch ORLYNVAHâ„¢, its first branded antibiotic for uncomplicated urinary tract infections, in August 2025. The company has partnered with EVERSANA for commercialization and has sufficient cash runway into 2026.
Iterum Therapeutics announced a partnership with EVERSANA to commercialize its approved product ORLYNVAHTM, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections, in the U.S. by Q4 2025.
